Ultragenyx Settles Dojolvi Patent Litigation With Navinta
Bitget2026/10/19 13:08- Ultragenyx Pharmaceutical and Baylor Research Institute settled DOJOLVI patent litigation with Navinta on October 19, 2026.
- Navinta will receive a non-exclusive, royalty-free license to market generic DOJOLVI beginning January 1, 2033, subject to customary conditions and exceptions.
- The launch date would move to July 1, 2033, if DOJOLVI receives pediatric exclusivity.
- The litigation stemmed from Navinta's application for FDA approval of a generic version of DOJOLVI oral liquid.
- Similar DOJOLVI patent litigation against other generic applicants remains pending in the U.S. District Court for the District of New Jersey.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Schneider Electric shares drop due to €6 billion stock placement
Ford will recall 102,159 vehicles in the US.
Nvidia (NVDA.US) invests in four German AI startups, advancing its $10 billion Europe investment plan
Nvidia (NVDA.US) is increasing its investment in the European AI sector, announcing plans to support four German startups: Agile Robots, Avelios Medical, Mirelo, and Reflex Aerospace.
Phase 3 trial meets primary endpoint! Eli Lilly (LLY.US) plans to expand Omvoh's indication for the treatment of pediatric ulcerative colitis
On Monday, Eli Lilly announced plans to seek an expanded indication for its Omvoh injection after a successful late-stage trial in children with ulcerative colitis.
Crypto prices
More
